This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.
This page refreshes automatically every 30 mins. Press F5 to update manually
For a more detailed explanation of Upgrades/Downgrades see Link
Key: (?) = Upgraded, (?) = Downgraded, (-) = Maintained
Stock | Broker | Broker Rating | Action | Previous Close (p) | Target Price (p) | Action | Distance to TP |
Upgrades | – | – | – | – | – | – | – |
APR Energy | Numis Securities | Buy | ↑ | 112.25 | 425 | – | 278.6% |
ARM Holdings | AlphaValue | Add | ↑ | 1037 | 1215 | – | 17.2% |
AstraZeneca | AlphaValue | Add | ↑ | 4019 | 4366 | ↓ | 8.6% |
Bodycote | Numis Securities | Add | ↑ | 674 | 750 | ↓ | 11.3% |
Dolphin Capital | Panmure Gordon | Buy | ↑ | 20 | 25 | – | 25.0% |
Faroe Petroleum | Cantor Fitzgerald | Buy | ↑ | 85.25 | 101 | ↑ | 18.5% |
HSBC Holdings | AlphaValue | Buy | ↑ | 4481 | 669 | ↓ | -85.1% |
Investec | Goldman Sachs | Buy | ↑ | 572 | 691 | ↑ | 20.8% |
Kingfisher | AlphaValue | Add | ↑ | 347.3 | 377 | – | 8.6% |
Lamprell | Canaccord Genuity | Buy | New | 151 | 180 | New | 19.2% |
NMC Health | JPMorgan Cazenove | Overweight | New | 795 | 910 | New | 14.5% |
Rolls-Royce | AlphaValue | Buy | ↑ | 870 | 1025 | ↓ | 17.8% |
Royal Dutch Shell | Independent Research GmbH | Hold | ↑ | 1807 | 1849 | – | 2.3% |
Shire | AlphaValue | Buy | ↑ | 5095 | 6029 | ↓ | 18.3% |
Tullow Oil | Numis Securities | Buy | ↑ | 339.7 | 429 | – | 26.3% |
WPP | AlphaValue | Buy | ↑ | 1426 | 1677 | ↓ | 17.6% |
Downgrades | – | – | – | – | – | – | – |
Anite | Numis Securities | Hold | ↓ | 127 | 131 | ↑ | 3.1% |
G4S | Nordea | Sell | New | 268.6 | 256.5 | New | -4.5% |
Tullett Prebon | Canaccord Genuity | Hold | ↓ | 366.9 | 375 | ↑ | 2.2% |
Stagecoach Group | RBC Capital Markets | Sector perform | ↓ | 403.8 | 425 | ↑ | 5.3% |
William Hill | Morgan Stanley | Equalweight | ↓ | 403.1 | 450 | – | 11.6% |
Target Price Changes | – | – | – | – | – | – | – |
Berkeley Group | Credit Suisse | Neutral | – | 3346 | 2814 | ↑ | -15.9% |
Betfair | Morgan Stanley | Overweight | – | 2406 | 3000 | ↑ | 24.7% |
FirstGroup | Morgan Stanley | Equalweight | – | 119.5 | 135 | ↑ | 13.0% |
Hargreaves Lansdown | JPMorgan Cazenove | Neutral | – | 1153 | 1160 | ↑ | 0.6% |
Helical Bar | JPMorgan Cazenove | Overweight | – | 403.5 | 470 | ↑ | 16.5% |
Lonmin | CIBC World Markets | Sector underperform | – | 111.9 | 125 | ↓ | 11.7% |
Paragon Grp | Jefferies | Buy | – | 414.2 | 540 | ↑ | 30.4% |
Pearson | Credit Suisse | Outperform | – | 1205 | 1455 | ↓ | 20.7% |
Pets At Home | Liberum | Buy | – | 298.7 | 360 | ↑ | 20.5% |
Rio Tinto | Macquarie | Neutral | – | 2614 | 3200 | ↓ | 22.4% |
Rolls-Royce | JPMorgan Cazenove | Neutral | – | 870 | 900 | ↓ | 3.4% |
Royal Bank of Scotland | Macquarie | Underperform | – | 351.5 | 330 | ↓ | -6.1% |
Serco | JPMorgan Cazenove | Neutral | – | 118 | 164 | ↓ | 39.0% |
Serco | Canaccord Genuity | Sell | – | 118 | 105 | ↓ | -11.0% |
Thomas Cook | Credit Suisse | Outperform | – | 136.8 | 165 | ↓ | 20.6% |
WPP | Bernstein | Outperform | – | 1426 | 1850 | ↓ | 29.7% |
Source: Bloomberg, Reuters News, AlphaTerminal, Dow Jones Newswires
T111his research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.
Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance. Prepared by Michael van Dulken, Head of Research